Recent Advances in the Management of Pediatric Acute Myeloid Leukemia—Report of the Hungarian Pediatric Oncology-Hematology Group
Outcome measures of pediatric acute myeloid leukemia (AML) improved considerably between 1990 and 2011 in Hungary. Since 2012, efforts of the Hungarian Pediatric Oncology-Hematology Group (HPOG) included the reduction in the number of treatment centers, contemporary diagnostic procedures, vigorous s...
Gespeichert in:
| Veröffentlicht in: | Cancers 2021-10, Vol.13 (20), p.5078 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 20 |
| container_start_page | 5078 |
| container_title | Cancers |
| container_volume | 13 |
| creator | Gaál, Zsuzsanna Jakab, Zsuzsanna Kárai, Bettina Ujfalusi, Anikó Petrás, Miklós Kállay, Krisztián Kelemen, Ágnes Simon, Réka Kriván, Gergely Kovács, Gábor T. Kiss, Csongor Szegedi, István |
| description | Outcome measures of pediatric acute myeloid leukemia (AML) improved considerably between 1990 and 2011 in Hungary. Since 2012, efforts of the Hungarian Pediatric Oncology-Hematology Group (HPOG) included the reduction in the number of treatment centers, contemporary diagnostic procedures, vigorous supportation, enhanced access to hematopoietic stem cell transplantation (HSCT), and to targeted therapies. The major aim of our study was to evaluate AML treatment results of HPOG between 2012 and 2019 with 92 new patients registered (52 males, 40 females, mean age 7.28 years). Two periods were distinguished: 2012–2015 and 2016–2019 (55 and 37 patients, respectively). During these periods, 2 y OS increased from 63.6% to 71.4% (p = 0.057), and the 2 y EFS increased significantly from 56.4% to 68.9% (p = 0.02). HSCT was performed in 37 patients (5 patients received a second HSCT). We demonstrate advances in the diagnosis and treatment of acute promyelocytic leukemia (APL) in two cases. Early diagnosis and follow-up were achieved by multidimensional flow cytometry and advanced molecular methods. Both patients were successfully treated with all-trans retinoic acid and arsenic-trioxide, in addition to chemotherapy. In order to meet international standards of pediatric AML management, HPOG will further centralize treatment centers and diagnostic facilities and join efforts with international study groups. |
| doi_str_mv | 10.3390/cancers13205078 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8534106</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2584342920</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-400070dadf159eb0a18cf086f00a12f1bd5710860e6fe278b14b4fba48b488d33</originalsourceid><addsrcrecordid>eNpdkc1q3DAUhUVoSYY062wN3XTjRH-25U1hGNpMYUpKSNZClq8mSmxpKtmB2RXyCnnCPEnlSSjT0UZHnO8edLgInRN8wViNL7VyGkIkjOICV-IIzSiuaF6WNf-wp0_QWYwPOB3GSFVWx-iE8VJgSosZer4BDW7I5u3TlBYz67LhHrKfyqk19JPlTfYLWquGYHU21-OQ3C103rbZCsZH6K16_fNyAxsfdvA0vhzdWgWr3N7otdO-8-ttvoReDTuZXQU_bj6hj0Z1Ec7e71N09_3b7WKZr66vfizmq1yzWgw5Tw0q3KrWkKKGBisitMGiNDhJakjTFhVJbwylAVqJhvCGm0Zx0XAhWsZO0de33M3Y9NBOvYPq5CbYXoWt9MrK_x1n7-XaP0lRME5wmQK-vAcE_3uEOMjeRg1dpxz4MUpaCF4JXJIioZ8P0Ac_Bpfq7SjGaU1xoi7fKB18jAHMv88QLKcdy4Mds7_3LZyJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2584342920</pqid></control><display><type>article</type><title>Recent Advances in the Management of Pediatric Acute Myeloid Leukemia—Report of the Hungarian Pediatric Oncology-Hematology Group</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>PubMed Central</source><creator>Gaál, Zsuzsanna ; Jakab, Zsuzsanna ; Kárai, Bettina ; Ujfalusi, Anikó ; Petrás, Miklós ; Kállay, Krisztián ; Kelemen, Ágnes ; Simon, Réka ; Kriván, Gergely ; Kovács, Gábor T. ; Kiss, Csongor ; Szegedi, István</creator><creatorcontrib>Gaál, Zsuzsanna ; Jakab, Zsuzsanna ; Kárai, Bettina ; Ujfalusi, Anikó ; Petrás, Miklós ; Kállay, Krisztián ; Kelemen, Ágnes ; Simon, Réka ; Kriván, Gergely ; Kovács, Gábor T. ; Kiss, Csongor ; Szegedi, István</creatorcontrib><description>Outcome measures of pediatric acute myeloid leukemia (AML) improved considerably between 1990 and 2011 in Hungary. Since 2012, efforts of the Hungarian Pediatric Oncology-Hematology Group (HPOG) included the reduction in the number of treatment centers, contemporary diagnostic procedures, vigorous supportation, enhanced access to hematopoietic stem cell transplantation (HSCT), and to targeted therapies. The major aim of our study was to evaluate AML treatment results of HPOG between 2012 and 2019 with 92 new patients registered (52 males, 40 females, mean age 7.28 years). Two periods were distinguished: 2012–2015 and 2016–2019 (55 and 37 patients, respectively). During these periods, 2 y OS increased from 63.6% to 71.4% (p = 0.057), and the 2 y EFS increased significantly from 56.4% to 68.9% (p = 0.02). HSCT was performed in 37 patients (5 patients received a second HSCT). We demonstrate advances in the diagnosis and treatment of acute promyelocytic leukemia (APL) in two cases. Early diagnosis and follow-up were achieved by multidimensional flow cytometry and advanced molecular methods. Both patients were successfully treated with all-trans retinoic acid and arsenic-trioxide, in addition to chemotherapy. In order to meet international standards of pediatric AML management, HPOG will further centralize treatment centers and diagnostic facilities and join efforts with international study groups.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers13205078</identifier><identifier>PMID: 34680225</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Acute myeloid leukemia ; Acute promyeloid leukemia ; Arsenic ; Bone marrow ; Chemotherapy ; Diagnosis ; Disease prevention ; Flow cytometry ; Hematology ; Hematopoietic stem cells ; International standards ; Labeling ; Laboratories ; Leukemia ; Myeloid leukemia ; Oncology ; Patients ; Pediatrics ; Promyeloid leukemia ; Retinoic acid ; Statistical analysis ; Stem cell transplantation</subject><ispartof>Cancers, 2021-10, Vol.13 (20), p.5078</ispartof><rights>2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 by the authors. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-400070dadf159eb0a18cf086f00a12f1bd5710860e6fe278b14b4fba48b488d33</citedby><cites>FETCH-LOGICAL-c398t-400070dadf159eb0a18cf086f00a12f1bd5710860e6fe278b14b4fba48b488d33</cites><orcidid>0000-0002-4328-9612 ; 0000-0001-5170-5965</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534106/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534106/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Gaál, Zsuzsanna</creatorcontrib><creatorcontrib>Jakab, Zsuzsanna</creatorcontrib><creatorcontrib>Kárai, Bettina</creatorcontrib><creatorcontrib>Ujfalusi, Anikó</creatorcontrib><creatorcontrib>Petrás, Miklós</creatorcontrib><creatorcontrib>Kállay, Krisztián</creatorcontrib><creatorcontrib>Kelemen, Ágnes</creatorcontrib><creatorcontrib>Simon, Réka</creatorcontrib><creatorcontrib>Kriván, Gergely</creatorcontrib><creatorcontrib>Kovács, Gábor T.</creatorcontrib><creatorcontrib>Kiss, Csongor</creatorcontrib><creatorcontrib>Szegedi, István</creatorcontrib><title>Recent Advances in the Management of Pediatric Acute Myeloid Leukemia—Report of the Hungarian Pediatric Oncology-Hematology Group</title><title>Cancers</title><description>Outcome measures of pediatric acute myeloid leukemia (AML) improved considerably between 1990 and 2011 in Hungary. Since 2012, efforts of the Hungarian Pediatric Oncology-Hematology Group (HPOG) included the reduction in the number of treatment centers, contemporary diagnostic procedures, vigorous supportation, enhanced access to hematopoietic stem cell transplantation (HSCT), and to targeted therapies. The major aim of our study was to evaluate AML treatment results of HPOG between 2012 and 2019 with 92 new patients registered (52 males, 40 females, mean age 7.28 years). Two periods were distinguished: 2012–2015 and 2016–2019 (55 and 37 patients, respectively). During these periods, 2 y OS increased from 63.6% to 71.4% (p = 0.057), and the 2 y EFS increased significantly from 56.4% to 68.9% (p = 0.02). HSCT was performed in 37 patients (5 patients received a second HSCT). We demonstrate advances in the diagnosis and treatment of acute promyelocytic leukemia (APL) in two cases. Early diagnosis and follow-up were achieved by multidimensional flow cytometry and advanced molecular methods. Both patients were successfully treated with all-trans retinoic acid and arsenic-trioxide, in addition to chemotherapy. In order to meet international standards of pediatric AML management, HPOG will further centralize treatment centers and diagnostic facilities and join efforts with international study groups.</description><subject>Acute myeloid leukemia</subject><subject>Acute promyeloid leukemia</subject><subject>Arsenic</subject><subject>Bone marrow</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Disease prevention</subject><subject>Flow cytometry</subject><subject>Hematology</subject><subject>Hematopoietic stem cells</subject><subject>International standards</subject><subject>Labeling</subject><subject>Laboratories</subject><subject>Leukemia</subject><subject>Myeloid leukemia</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Promyeloid leukemia</subject><subject>Retinoic acid</subject><subject>Statistical analysis</subject><subject>Stem cell transplantation</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkc1q3DAUhUVoSYY062wN3XTjRH-25U1hGNpMYUpKSNZClq8mSmxpKtmB2RXyCnnCPEnlSSjT0UZHnO8edLgInRN8wViNL7VyGkIkjOICV-IIzSiuaF6WNf-wp0_QWYwPOB3GSFVWx-iE8VJgSosZer4BDW7I5u3TlBYz67LhHrKfyqk19JPlTfYLWquGYHU21-OQ3C103rbZCsZH6K16_fNyAxsfdvA0vhzdWgWr3N7otdO-8-ttvoReDTuZXQU_bj6hj0Z1Ec7e71N09_3b7WKZr66vfizmq1yzWgw5Tw0q3KrWkKKGBisitMGiNDhJakjTFhVJbwylAVqJhvCGm0Zx0XAhWsZO0de33M3Y9NBOvYPq5CbYXoWt9MrK_x1n7-XaP0lRME5wmQK-vAcE_3uEOMjeRg1dpxz4MUpaCF4JXJIioZ8P0Ac_Bpfq7SjGaU1xoi7fKB18jAHMv88QLKcdy4Mds7_3LZyJ</recordid><startdate>20211011</startdate><enddate>20211011</enddate><creator>Gaál, Zsuzsanna</creator><creator>Jakab, Zsuzsanna</creator><creator>Kárai, Bettina</creator><creator>Ujfalusi, Anikó</creator><creator>Petrás, Miklós</creator><creator>Kállay, Krisztián</creator><creator>Kelemen, Ágnes</creator><creator>Simon, Réka</creator><creator>Kriván, Gergely</creator><creator>Kovács, Gábor T.</creator><creator>Kiss, Csongor</creator><creator>Szegedi, István</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4328-9612</orcidid><orcidid>https://orcid.org/0000-0001-5170-5965</orcidid></search><sort><creationdate>20211011</creationdate><title>Recent Advances in the Management of Pediatric Acute Myeloid Leukemia—Report of the Hungarian Pediatric Oncology-Hematology Group</title><author>Gaál, Zsuzsanna ; Jakab, Zsuzsanna ; Kárai, Bettina ; Ujfalusi, Anikó ; Petrás, Miklós ; Kállay, Krisztián ; Kelemen, Ágnes ; Simon, Réka ; Kriván, Gergely ; Kovács, Gábor T. ; Kiss, Csongor ; Szegedi, István</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-400070dadf159eb0a18cf086f00a12f1bd5710860e6fe278b14b4fba48b488d33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Acute myeloid leukemia</topic><topic>Acute promyeloid leukemia</topic><topic>Arsenic</topic><topic>Bone marrow</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Disease prevention</topic><topic>Flow cytometry</topic><topic>Hematology</topic><topic>Hematopoietic stem cells</topic><topic>International standards</topic><topic>Labeling</topic><topic>Laboratories</topic><topic>Leukemia</topic><topic>Myeloid leukemia</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Promyeloid leukemia</topic><topic>Retinoic acid</topic><topic>Statistical analysis</topic><topic>Stem cell transplantation</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gaál, Zsuzsanna</creatorcontrib><creatorcontrib>Jakab, Zsuzsanna</creatorcontrib><creatorcontrib>Kárai, Bettina</creatorcontrib><creatorcontrib>Ujfalusi, Anikó</creatorcontrib><creatorcontrib>Petrás, Miklós</creatorcontrib><creatorcontrib>Kállay, Krisztián</creatorcontrib><creatorcontrib>Kelemen, Ágnes</creatorcontrib><creatorcontrib>Simon, Réka</creatorcontrib><creatorcontrib>Kriván, Gergely</creatorcontrib><creatorcontrib>Kovács, Gábor T.</creatorcontrib><creatorcontrib>Kiss, Csongor</creatorcontrib><creatorcontrib>Szegedi, István</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gaál, Zsuzsanna</au><au>Jakab, Zsuzsanna</au><au>Kárai, Bettina</au><au>Ujfalusi, Anikó</au><au>Petrás, Miklós</au><au>Kállay, Krisztián</au><au>Kelemen, Ágnes</au><au>Simon, Réka</au><au>Kriván, Gergely</au><au>Kovács, Gábor T.</au><au>Kiss, Csongor</au><au>Szegedi, István</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent Advances in the Management of Pediatric Acute Myeloid Leukemia—Report of the Hungarian Pediatric Oncology-Hematology Group</atitle><jtitle>Cancers</jtitle><date>2021-10-11</date><risdate>2021</risdate><volume>13</volume><issue>20</issue><spage>5078</spage><pages>5078-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Outcome measures of pediatric acute myeloid leukemia (AML) improved considerably between 1990 and 2011 in Hungary. Since 2012, efforts of the Hungarian Pediatric Oncology-Hematology Group (HPOG) included the reduction in the number of treatment centers, contemporary diagnostic procedures, vigorous supportation, enhanced access to hematopoietic stem cell transplantation (HSCT), and to targeted therapies. The major aim of our study was to evaluate AML treatment results of HPOG between 2012 and 2019 with 92 new patients registered (52 males, 40 females, mean age 7.28 years). Two periods were distinguished: 2012–2015 and 2016–2019 (55 and 37 patients, respectively). During these periods, 2 y OS increased from 63.6% to 71.4% (p = 0.057), and the 2 y EFS increased significantly from 56.4% to 68.9% (p = 0.02). HSCT was performed in 37 patients (5 patients received a second HSCT). We demonstrate advances in the diagnosis and treatment of acute promyelocytic leukemia (APL) in two cases. Early diagnosis and follow-up were achieved by multidimensional flow cytometry and advanced molecular methods. Both patients were successfully treated with all-trans retinoic acid and arsenic-trioxide, in addition to chemotherapy. In order to meet international standards of pediatric AML management, HPOG will further centralize treatment centers and diagnostic facilities and join efforts with international study groups.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>34680225</pmid><doi>10.3390/cancers13205078</doi><orcidid>https://orcid.org/0000-0002-4328-9612</orcidid><orcidid>https://orcid.org/0000-0001-5170-5965</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2021-10, Vol.13 (20), p.5078 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8534106 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; PubMed Central |
| subjects | Acute myeloid leukemia Acute promyeloid leukemia Arsenic Bone marrow Chemotherapy Diagnosis Disease prevention Flow cytometry Hematology Hematopoietic stem cells International standards Labeling Laboratories Leukemia Myeloid leukemia Oncology Patients Pediatrics Promyeloid leukemia Retinoic acid Statistical analysis Stem cell transplantation |
| title | Recent Advances in the Management of Pediatric Acute Myeloid Leukemia—Report of the Hungarian Pediatric Oncology-Hematology Group |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T19%3A27%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20Advances%20in%20the%20Management%20of%20Pediatric%20Acute%20Myeloid%20Leukemia%E2%80%94Report%20of%20the%20Hungarian%20Pediatric%20Oncology-Hematology%20Group&rft.jtitle=Cancers&rft.au=Ga%C3%A1l,%20Zsuzsanna&rft.date=2021-10-11&rft.volume=13&rft.issue=20&rft.spage=5078&rft.pages=5078-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers13205078&rft_dat=%3Cproquest_pubme%3E2584342920%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2584342920&rft_id=info:pmid/34680225&rfr_iscdi=true |